Momenta Pharmaceuticals, Inc.
MNTA
MNTA was delisted on the 30th of September, 2020.
170 hedge funds and large institutions have $2.33B invested in Momenta Pharmaceuticals, Inc. in 2019 Q4 according to their latest regulatory filings, with 35 funds opening new positions, 69 increasing their positions, 40 reducing their positions, and 14 closing their positions.
362% more call options, than puts
Call options by funds: $5.31M | Put options by funds: $1.15M
150% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 14
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
83% more capital invested
Capital invested by funds: $1.27B → $2.33B (+$1.05B)
73% more repeat investments, than reductions
Existing positions increased: 69 | Existing positions reduced: 40
10% more funds holding
Funds holding: 154 → 170 (+16)
4.36% more ownership
Funds ownership: 99.43% → 103.79% (+4.4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
+$51.8M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$44M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$40.8M |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$28.6M |
| 5 |
BlackRock
New York
|
+$24M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$15.4M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$12.7M |
| 3 |
Renaissance Technologies
New York
|
-$8.52M |
| 4 |
Millennium Management
New York
|
-$5.55M |
| 5 |
Westfield Capital Management
Boston,
Massachusetts
|
-$4.47M |
MNTA Hedge Fund Activity: Q4 2019 in Review
170 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in Momenta Pharmaceuticals, Inc. (MNTA) for Q4 2019, worth a combined $2.33B — up 83% from $1.27B a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new MNTA positions and 14 closed out — a net gain of 21 holders — while 69 added to existing stakes and 40 trimmed.
The largest buyer was Redmile Group, opening a new position worth an estimated $51.8M. The largest seller was Point72 Asset Management, cutting an estimated $15.4M.
- 170 institutional investors held Momenta Pharmaceuticals, Inc. (MNTA) as of Q4 2019, up from 154 in Q3 2019.
- Funds reported $2.33B of Momenta Pharmaceuticals, Inc. stock for Q4 2019, up 83% quarter-over-quarter.
- 35 funds opened new Momenta Pharmaceuticals, Inc. positions in Q4 2019 and 14 closed out, a net change of +21 holders.
- The largest Momenta Pharmaceuticals, Inc. buyer in Q4 2019 was Redmile Group, an estimated $51.8M added.
- The largest Momenta Pharmaceuticals, Inc. seller in Q4 2019 was Point72 Asset Management, an estimated $15.4M sold.
Based on aggregated 13F filings for Q4 2019.